39 completed, 11 terminated, 5 unknown, 4 withdrawn. 19 Phase 4, 14 Phase 2, 14 Phase 3, 9 Phase 1.
Follow Micafungin: new trials by email Literature Review of Micafungin trials Research Report on Micafungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antimicrobial Revision in Persistent Febrile Neutropenia Meropenem, Micafungin - Febrile Neutropenia | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2024-08-01 | 2024-09-19 | |
| Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection Micafungin, Amphotericin B - Neonatal Infection, Invasive Fungal Infections | Phase 4 | Completed | Ain Shams University | 56 | 2022-10-20 | 2024-05-16 |
| To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation Micafungin Sodium 50 MG Injection, Caspofungin Acetate - Liver Transplantation | Phase 4 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 200 | 2022-10-01 | 2022-08-16 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Evaluate Bioequivalence of Micafungin (50mg/Vial) Micafungin - Invasive Candidiasis | Phase 4 | Completed | Yung Shin Pharm. Ind. Co., Ltd. | 14 | 2022-01-06 | 2022-08-11 |
| Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors Micafungin Sodium - Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | Phase 4 | Unknown | Shandong Provincial Hospital | 230 | 2021-02-01 | 2021-02-04 |
| Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin 1,3-β-D-glucan quantification, Micafungin - Invasive Candidiasis | Phase 4 | Terminated | Fadoi Foundation, Italy | 14 | 2018-07-18 | 2021-04-12 |
| Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study Micafungin - Invasive Fungal Infections | Completed | Astellas Pharma Singapore Pte. Ltd. | 120 | 2017-06-21 | 2024-10-21 | |
| Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study) Echinocandins - Septic Shock, Peritonitis | Phase 4 | Completed | Centre Hospitalier Universitaire de Nīmes | 24 | 2017-01-28 | 2025-12-10 |
| Micafungin Pharmacokinetics in Obese Patients Micafungin - Morbid Obesity | Phase 4 | Completed | Radboud University Medical Center | 24 | 2017-01-01 | 2020-10-19 |
| Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Micafungin - Acute Leukemia | Phase 2 | Completed | Seoul National University Hospital | 66 | 2015-09-19 | 2021-11-09 |
| Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis Micafungin - Candidiasis, Systemic, Candida Meningitis | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 35 | 2015-05-30 | 2024-11-18 |
| A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections Micafungin - Invasive Fungal Infections | Completed | Astellas Pharma China, Inc. | 2555 | 2015-03-01 | 2016-02-10 | |
| Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease alternate dosing, daily dosing, micafungin - Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant | Phase 2 | Completed | Radboud University Medical Center | 30 | 2014-10-01 | 2020-12-08 |
| Fluconazole Versus Micafungin in Neonates With Candidiasis Fluconazole, Micafungin - Candidiasis | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 100 | 2014-10-01 | 2025-09-04 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive | Phase 2 | Completed | Scynexis, Inc. | 27 | 2014-09-01 | 2024-06-25 |
| Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology Micafungin - Antifungal Prophylaxis, Haemopathy | Completed | Astellas Pharma S.A.S. | 150 | 2014-07-03 | 2024-10-21 | |
| Pharmacokinetics of Micafungin in Patients of Intensive Care Units micafungin - Invasive Candidiasis | Phase 4 | Completed | University Hospital, Limoges | 60 | 2014-06-01 | 2025-11-21 |
| Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Micafungin - Aspergillosis, Candidiasis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 105 | 2014-03-21 | 2024-11-07 |
| Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Micafungin - Invasive Aspergillosis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 43 | 2014-03-01 | 2024-11-20 |
Showing 20 of 59. Sign in to see all of them.
Candidemia (12) · Candidiasis (12) · Candidiasis, Invasive (12) · Invasive Fungal Infections (12) · Aspergillosis (10) · Mycoses (10) · Torulopsis (4) · Fungemia (3) · Leukemia, Myeloid, Acute (3) · Neutropenia (3) · Candidiasis, Oral (2) · Febrile Neutropenia (2) · Body Weight (1) · Fever (1) · Graft vs Host Disease (1)
Astellas Pharma Inc (18) · Astellas Pharma China, Inc. (4) · Radboud University Medical Center (3) · Asan Medical Center (2) · Astellas Pharma Global Development, Inc. (2) · Children's Hospital Medical Center, Cincinnati (2) · National Cancer Institute (NCI) (2) · Scynexis, Inc. (2) · Seoul National University Hospital (2) · Ain Shams University (1) · Astellas Pharma S.A.S. (1) · Astellas Pharma Singapore Pte. Ltd. (1) · Centre Hospitalier Universitaire de Nīmes (1) · Fadoi Foundation, Italy (1) · Gary E. Stein, Pharm.D. (1)
United States (22) · France (13) · Italy (9) · Germany (8) · Spain (8) · Belgium (7) · China (7) · Austria (6) · South Korea (6) · Brazil (5) · Canada (5) · Netherlands (5) · United Kingdom (5) · Hungary (4) · Poland (4)
David Angulo, MD (2) · Parinda Mehta, MD (2) · Claire Roger, MD (1) · Dong-Lak Choi, Professor (1) · Elias Anaissie, MD (1) · Florian Thalhammer, Prof. Dr. (1) · Gary E Stein, Pharm.D. (1) · Genovefa Papanicolaou, MD (1) · Giwon Song, Professor (1)
PMID 21147825, PMID 23959319, PMID 16678903, PMID 18983417, PMID 19804626, PMID 22469884, PMID 24261608, PMID 25520332, PMID 25963988, PMID 26270686, PMID 27706483, PMID 28584142, PMID 29596222, PMID 29744900, PMID 30105657, PMID 30137340, PMID 30649375, PMID 30991992, PMID 31066013, PMID 32914187, PMID 33558294, PMID 33846133, PMID 40016807, PMID 41219680
2008 (2), 2014 (1), 2016 (1)